seizures

Canavan Disease

Clinical Characteristics
Ocular Features: 

Optic atrophy is the primary and perhaps only ocular manifestation of Canavan disease.  Acuity levels have not been reported but it has been noted that some infants and young children with early onset severe disease are able to track targets.  The ocular phenotype has not been well delineated.

Systemic Features: 

The clinical diagnosis of Canavan disease is suggested when the triad of hypotonia, macrocephaly and head lag is present.  It is a progressive form of spongy degeneration of the central nervous system but its onset, course, and severity are variable.

The disease is often evident before 6 months of age and survival is limited to a few months or years in infants with such early onset.  Such patients have the most severe and rapidly progressive disease.  It is noteworthy that, even though such infants do not achieve normal milestones such as sitting and standing, they do often interact socially by laughing, smiling, and reaching for objects.  Most young children are quiet and apathetic but some become irritable and develop spasticity as they grow.  CNS damage is evident as leukodystrophy on neuroimaging studies but this may not be present in later onset, milder forms of the disease.         

Other individuals may have a later and milder juvenile onset of symptoms and may present with delayed speech or motor development late in the first decade.  They often attend regular school but may benefit from tutoring and speech therapy.  They may live to adolescence or early adulthood.  Maldevelopment of the organ of Corti is responsible for hearing deficits in some children.

Genetics

Canavan disease is an autosomal recessive disorder resulting from homozygous or compound heterozygous mutations in the gene (ASPA) located at 17p13.2 encoding the enzyme aspartoacylase.  N-acetylaspartic acid (NAA) levels are usually elevated in urine.  However, because the levels of NAA can vary depending on the severity of clinical disease, gene testing provides a more reliable diagnosis. 

The carrier frequency is high among members of the Ashkenazi Jewish population.

Pedigree: 
Autosomal recessive
Treatment
Treatment Options: 

Antiepileptic drugs can be helpful.  Augmented feeding (gastric tubes)may be needed to maintain nutrition, while physical therapy and exercise may prevent contractures.  Speech therapy and low vision aids might be of benefit. Rare patients with a hearing deficit should be evaluated for possible benefit of hearing aids.

References
Article Title: 

Cataracts, Congenital, and Hypomyelinating Leukodystrophy

Clinical Characteristics
Ocular Features: 

Bilateral cataracts may be present at birth or later in the first decade of life.  The ERG and flash VEPs are normal.

Systemic Features: 

Psychomotor development is initially normal but signs of delay are usually present during the first year of life.  Patients may be able to walk but only with support.  Pyramidal and cerebellar dysfunction, muscle weakness and wasting, dysarthria, truncal hypotonia, intention tremor, and spasticity are evident during the first decade.  Some have seizures.  Cognitive impairment ranges from mild to moderate.  Most patients become wheelchair-bound late in the first decade of life and some do not survive beyond childhood.

Hypomyelination and mild axonal loss may be seen in peripheral nerve biopsies while neuroimaging shows evidence of diffuse and progressive cerebral white matter atrophy.

Genetics

This is an autosomal recessive disorder caused by homozygous mutations in FAM126A (7p15.3) leading to a deficiency of the neuronal protein hyccin.  The result is deficient myelination in both central and peripheral nervous systems.  No symptoms are evident in heterozygotes.

Pedigree: 
Autosomal recessive
Treatment
Treatment Options: 

The cataracts may be surgically removed.  There is no known treatment for the progressive neurologic deterioration but physical therapy and special education may be helpful.

References
Article Title: 

Novel FAM126A mutations in Hypomyelination and Congenital Cataract disease

Traverso M, Assereto S, Gazzerro E, Savasta S, Abdalla EM, Rossi A, Baldassari S, Fruscione F, Ruffinazzi G, Fassad MR, El Beheiry A, Minetti C, Zara F, Biancheri R. Novel FAM126A mutations in Hypomyelination and Congenital Cataract disease. Biochem Biophys Res Commun. 2013 Aug 30. [Epub ahead of print] PubMed PMID: 23998934.

PubMed ID: 
23998934

Phenotypic characterization of hypomyelination and congenital cataract

Biancheri R, Zara F, Bruno C, Rossi A, Bordo L, Gazzerro E, Sotgia F, Pedemonte M, Scapolan S, Bado M, Uziel G, Bugiani M, Lamba LD, Costa V, Schenone A, Rozemuller AJ, Tortori-Donati P, Lisanti MP, van der Knaap MS, Minetti C. Phenotypic characterization of hypomyelination and congenital cataract. Ann Neurol. 2007 Aug;62(2):121-7.

PubMed ID: 
17683097

Congenital Disorder of Glycosylation, Type Ij

Clinical Characteristics
Ocular Features: 

Bilateral cataracts are present at birth.  Nystagmus, strabismus, and long eyelashes have been reported.

Systemic Features: 

This is a disorder of glycosylation important to the formation of glycoproteins and glycolipids.  Neurological signs such as tremor, clonus, and muscle fasiculations may be seen soon after birth.  Other neurological abnormalities eventually include psychomotor retardation, seizures, mental retardation, hyperexcitabilty, and ataxia.  Failure to thrive and feeding difficulties are evident early.  Progressive microcephaly is a feature.  Liver dysfunction can lead to coagulopathy and hypoproteinemia with hepatomegaly is sometimes present.  Some patients have facial anomalies, inverted nipples, and subcutaneous fat pads.  The MRI may show areas of brain atrophy, ischemia, and focal necrosis.

Longevity is limited with 2 of 3 reported patients dying within 2 years of life.

Genetics

This is a rare autosomal recessive disorder resulting from mutations in DPAGT1 (11q23.3) resulting in defective N-glycosylation.  There are numerous other types of glycosylation defects with variations in the clinical manifestations.

Pedigree: 
Autosomal recessive
Treatment
Treatment Options: 

Treatment consists of fluid and caloric intake management.  Hypoproteinemia and coagulation defects may respond to oral mannose administration.

References
Article Title: 

Leukoencephalopathy with Vanishing White Matter

Clinical Characteristics
Ocular Features: 

Optic atrophy is a common feature and blindness is often the result.

Systemic Features: 

Onset of symptoms may occur at any time from 1.5 years of age to adulthood.  Early psychomotor development may be normal but developmental milestones such as walking and crawling are often delayed.  Patients with a later onset often have a milder course.  Progression is chronic but often episodic with exacerbations following infection and blunt head trauma. Mental stress, even of a relatively minor nature such as fright, may likewise cause a worsening of symptoms.  Such episodes can lead to loss of consciousness or even coma.  Cerebellar ataxia and spasticity are common.  Epilepsy may occur but is uncommon.  Motor function is more severely impaired compared with mental deterioration.  The MRI reveals a diffuse leukoencephalopathy as well as focal and cystic degeneration of white matter which may be present before the onset of symptoms.  Cerebellar atrophy primarily involving the vermis is common.  Behavioral problems, psychiatric symptoms, and even signs of dementia have been reported.  The vast majority of patients have cognitive disabilities and many become severely handicapped and immobile.  Early onset disease in children often leads to death within a few years whereas adults with later onset may live for many years.       

Females with leukoencephalopathy who live to puberty may experience ovarian failure, a condition sometimes called ovarioleukodystrophy.

Genetics

This is an autosomal recessive disorder secondary to homozygous mutations in one of a group of five genes (EIF2B) located on chromosomes 1,2,3,12, and 14 encoding subunits of translation initiation factor 2B.    

Pedigree: 
Autosomal recessive
Treatment
Treatment Options: 

There is no effective treatment for the neurologic disease.  Ocular treatment for cataracts has not been reported.

References
Article Title: 

Cerebral Cavernous Malformations

Clinical Characteristics
Ocular Features: 

Cavernous capillary hemangiomas usually occur singly in the fundus, often at the disc.  Fewer than 5% of individuals with CCM have retinal lesions.  As opposed to the systemic hemangiomas, those in the eye tend to be stable.  However, they may result in vitreous hemorrhages because they lack the usual structural support of normal vessels.  Fluorescein angiography often reveals blood-fluid levels in the saccules that comprise the grape-like cluster of the tumor.

Systemic Features: 

Cavernous angiomas may involve any part of the CNS, brain stem, and spinal cord.  These are benign aberrant growths of capillary endothelium which develop shortly after birth and cause a variety of signs and symptoms including seizures, intracranial hemorrhage, and focal neurologic deficits. New lesions can appear throughout life. The blood –containing clusters are lined with endothelium only and the walls lack muscle or fibrous tissue.  Up to 25% are diagnosed in children. They may be angiographically silent but MRI is diagnostically useful.  Cutaneous hemangiomas are uncommon but helpful diagnostically when present.  The overlying skin may be hyperkeratotic.

Many patients (25-50%) remain asymptomatic throughout life.

Genetics

This is an autosomal dominant disorder caused by mutations in three genes.  CCM1 (116860) results from mutations in the KRIT1 gene located at 7q11.2-q21, the disease called CCM2 (603284) is caused by mutations in the CCM2/malcavernin gene (7p13), and CCM3 (603285) by mutations in the PDCD10 gene at 3q26.1.  The majority of familial cases have mutations in one of these genes.

Pedigree: 
Autosomal dominant
Treatment
Treatment Options: 

The fundus lesions seldom require treatment but photocoagulation can be used to seal those that lead to recurrent vitreous hemorrhages.  Embolism may be beneficial for CNS lesions but the lesions in many locations are relatively easy to remove surgically. Seizures are treated symptomatically.  Pharmaceutical agents that alter blood clotting should be administered with careful monitoring.

References
Article Title: 

Genotype-phenotype correlations in cerebral cavernous malformations patients

Denier C, Labauge P, Bergametti F, Marchelli F, Riant F, Arnoult M, Maciazek J, Vicaut E, Brunereau L, Tournier-Lasserve E; Soci?(c)t?(c) Fran?ssaise de Neurochirurgie. Genotype-phenotype correlations in cerebral cavernous malformations patients. Ann Neurol. 2006 Nov;60(5):550-6.

PubMed ID: 
17041941

MELAS Syndrome

Clinical Characteristics
Ocular Features: 

This progressive mitochondrial disorder primarily affects muscles and the CNS, including the visual system.  The pattern of ocular deficits is not consistent and those that are present are not specific, requiring the clinician to take the entire neurological picture into consideration.  Hemianopsia, cortical blindness and ophthalmoplegia may be present.  The ERG can show reduced b-wave amplitudes and VEPs may be absent.  The optic nerve head has been described as normal without the atrophy often seen with other mitochondrial disorders.  A pigmentary retinopathy may be present.

Systemic Features: 

The clinical picture is highly variable.  Most commonly patients have myopathy, encephalopathy, lactic acidosis, and stroke-like episodes.  The onset of symptoms is usually in the first two decades of life, most commonly consisting of headaches of sudden onset accompanied by vomiting and seizures.  The headaches may simulate migraines.  Weakness, lethargy, and apathy may be present early.  However, infants and young children may present with failure to thrive, developmental delay, and learning disabilities.  Neurosensory deafness is often seen and peripheral neuropathy is usually evident.  MRIs may show cerebellar hypoplasia and infarctions in the cerebral hemispheres.  Some patients have calcifications in the basal ganglia.  Patients may develop lactic acidosis.  Muscle biopsies often show ragged, red fibers.  The heart is commonly involved with both structural and rhythm defects.  Depending upon the degree and location of brain damage, patients may have hemiparesis, lethargy, ataxia, myoclonic jerks, cognitive decline, and dementia.  Morbidity and mortality are high.

Genetics

MELAS syndrome is a group of disorders caused by mutations in mitochondrial genes (at least 9 have been identified) that alter transfer RNA molecules resulting in disruption of intramitochondrial synthesis of proteins involved in oxidative phosphorylation pathways.  It is both clinically and genetically heterogeneous.  One can expect that any familial occurrence would result from maternal transmission but the occurrence of heteroplasmy results in considerable variability in the severity of clinical disease.

Treatment
Treatment Options: 

There is no effective treatment that prevents development of disease or that slows its progress.

References
Article Title: 

Organoid Nevus Syndrome

Clinical Characteristics
Ocular Features: 

The sebaceous nevi often involve the eyelids, cornea, and conjunctiva.  Dermoids and lipodermoids are also seen.  Iris and choroidal colobomas are often present.  The sclerae may contain cartilage and bone which can be visible on CAT scans.  Depending upon the structures involved, patients may have strabismus, nystagmus, ptosis, exposure keratitis, and nerve palsies.

 

Systemic Features: 

Phakomatous lesions on the skin seem to preferentially occur on the upper part of the body including the face, neck and scalp but they may occur anywhere on the body including the oral cavity.  Initially they appear as papules but become verrucous around puberty.  Malignant transformation is seen in 15-20 per cent of patients.

Mental retardation and seizures are often seen in the first year of life.  Milestones achieved during that time are often lost subsequently.  Generalized weakness, osteopenia, and intracranial aneurysms are features in some patients.  Bone involvement may be highly asymmetrical.

Biopsies of conjunctival lesions show choristomas containing hyperplastic sebaceous and apocrine glands along with hair follicles.

Genetics

No clear genetic basis exists for this disease.  However, several families with multigenerational involvement have been reported in an autosomal dominant pattern.  It has been suggested that the disorder may result from a dominant lethal gene that allows some patients to survive by chance mosaicism.

Treatment
Treatment Options: 

No treatment is available for the generalized disease but therapy for specific symptoms such as epilepsy may be helpful.

References
Article Title: 

Ophthalmic features of the organoid nevus syndrome

Shields JA, Shields CL, Eagle RC Jr, Arevalo F, De Potter P. Ophthalmic features of the organoid nevus syndrome. Trans Am Ophthalmol Soc. 1996;94:65-86; discussion 86-7. Review.

PubMed ID: 
8981690

Adrenoleukodystrophy, Autosomal

Clinical Characteristics
Ocular Features: 

This early onset and rapidly progressive form of adrenoleukodystrophy is rare.  The early onset and rapidly fatal course of the disease has limited full delineation of the ocular features.  The most striking is the presence of 'leopard-spots' pigmentary changes in the retina.  Polar cataracts, strabismus, and epicanthal folds have also been reported. 

Systemic Features: 

Onset of symptoms occurs shortly after birth often with seizures and evidence of psychomotor deficits.  Rapid neurologic deterioration begins at about 1 year of age with death usually by the age of 3 years.  Hyperpigmentation of the skin may be apparent a few months after birth.  Opisthotonus has been observed.  The ears may be low-set, the palate is highly arched, and the nostrils anteverted.  Frontal bossing may be present.  Serum pipecolic acid and very-long-chain fatty acids (VLCFAs) can be markedly elevated.  Cystic changes in the kidneys have been reported. 

Genetics

This is an autosomal recessive peroxismal disorder resulting from homozygous mutations in receptor gene mutations such as PEX1, PEX5, PEX13, and PEX26.

There is also an X-linked recessive adrenoleukodystrophy (300100) sometimes called ALD but it lacks some of the morphologic features and is somewhat less aggressive. 

Neonatal adrenoleukodystrophy along with infantile Refsum disease (266510, 601539) and Zellweger syndrome (214100) are now classified as Zellweger spectrum or perioxismal biogenesis disorders.

Pedigree: 
Autosomal recessive
Treatment
Treatment Options: 

Treatment is mainly supportive for associated health problems. 

References
Article Title: 

Neuraminidase Deficiency

Clinical Characteristics
Ocular Features: 

A cherry red spot is may be seen in late childhood or early adolescence.  It occurs in nearly 100% of patients with type I while only 75% of type II patients have this feature possibly because their early death from the more severe systemic disease prevents full ascertainment.  Visual acuity is reduced, sometimes severely.  Some but not all individuals have corneal and lens opacities.  A subtle corneal haze has also been seen.  Nystagmus has been reported. 

Systemic Features: 

This is a neurodegenerative disorder with progressive deterioration of muscle and central nervous system functions.  Myoclonus, mental deterioration, hepatosplenomegaly, muscle weakness and atrophy are common.  The defect in neuraminidase activity leads to abnormal amounts of sialyl-oligosaccharides in the urine.  Spinal deformities such as kyphosis are common.  Deep tendon reflexes are exaggerated.  Ataxia and hearing loss may be present.  Coarse facies, a barrel chest, and short stature are characteristic.  Hepatic cells contain numerous vacuoles and numerous inclusions.

Sialidosis types I and II are both caused by mutations in the neuroaminidase gene.  Type I is associated with milder disease than type II which has an earlier age of onset and may present in infancy or even begin in utero.  Early death within two years of age is common in the congenital or infantile forms.  There is, however, significant variability in age of onset and the course of disease among types. 

Genetics

The sialidoses are autosomal recessive lysosomal storage disorders resulting from mutations in the NEU1 gene (6p21.3) which lead to an intracellular accumulation of glycoproteins containing sialic acid residues.  Both types I and II are caused by mutations in the same gene. 

Treatment
Treatment Options: 

Treatment is focused on symptom management. 

References
Article Title: 

Sandhoff Disease

Clinical Characteristics
Ocular Features: 

Retinal ganglion cells are rendered dysfunctional from the toxic accumulation of intra-lysosomal GM2 ganglioside molecules causing early visual symptoms.  These cells in high density around the fovea centralis create a grayish-white appearance.  Since ganglion cells are absent in the foveolar region, this area retains the normal reddish appearance, producing the cherry-red spot.  Axonal decay and loss of the ganglion cells leads to optic atrophy and blindness. 

Systemic Features: 

Sandhoff disease may be clinically indistinguishable from Tay-Sachs disease even though the same enzyme is defective (albeit in separate subunits A and B that together comprise the functional enzymes).  The presence of hepatosplenomegaly in Sandoff disease may be distinguishing. The infantile form of this lysosomal storage disease seems to be the most severe.  Infants appear to be normal until about 3-6 months of age when neurological development slows and muscles become weak.  Seizures, loss of interest, and progressive paralysis begin after this together with loss of vision and hearing.  An exaggerated startle response is considered an early and helpful sign in the diagnosis.  Among infants with early onset disease, death usually occurs by 3 or 4 years of age.   

Ataxia with spinocerebellar degeneration, motor neuron disease, dementia, and progressive dystonia are more common in individuals with later onset of neurodegeneration.  The juvenile and adult-onset forms of the disease also progress more slowly.  

Genetics

Sandhoff disease results from mutations in the beta subunit of the hexosaminidase A and B enzymes.  It is an autosomal recessive disorder caused by mutations in HEXB (5q13). 

Tay-Sachs disease (272800) can be clinically indistinguishable from Sandoff disease and they are allelic disorders.  However, the mutation in Tay-Sachs (272800) is in HEXA resulting in dysfunction of the alpha subunit of hexosaminidase A enzyme. 

Pedigree: 
Autosomal recessive
Treatment
Treatment Options: 

No specific treatment is available beyond general support with proper nutrition and maintainence of airways.  Anticonvulsants may be helpful in some stages.  Gene therapy in fibroblast cultures has achieved some restoration of  hexosaminidase A activity in Tay-Sachs disease and may have potential in Sandhoff disease as well. 

References
Article Title: 

Pages

Subscribe to RSS - seizures